Avita Medical (ASX:AVH) share price jumps on FDA approval

Avita shares have landed in the green from the market open. Here are the details…
The post Avita Medical (ASX:AVH) share price jumps on FDA approval appeared first on The Motley Fool Australia. –

The Avita Medical Inc (ASX: AVH) share price is in the green in early afternoon trade. Avita shares are on the move after the company gained regulatory momentum overnight.

Let’s discuss further.

A quick refresher on Avita Medical

Avita Medical is a medical technology company that has expertise in regenerative medicine. Its flagship product is the revolutionary Recell system, used to help skin recover from burns.

In addition, Avita is trialling Recell on other domains such as soft tissue reconstruction and paediatric scald injuries.

At the time of writing, Avita Medical has a market capitalisation of $587 million.

What did Avita announce?

In a positive for the Avitia Medical share price, the company has realised some regulatory tailwinds overnight.

To illustrate, in an announcement Avita advised that the US Food and Drug Administration (FDA) approved the company’s request to amend its pivotal clinical trial investigating Recell’s application in vitiligo lesions.

Vitiligo is an autoimmune condition that results in the loss of pigmentation of skin.

Recall that Avita originally sought the “strategic decision” to amend its formulation “based on data from other research efforts”.

Avita’s decision effectively restructures and simplifies the study design. Therefore, the company can progress the program “in a timely and cost-effective manner”.

Moreover, the program “is on track” and Avita is confident it could have Recell available for vitiligo applications “as early as the second half of calendar year 2023”.

In addition, the new “single-arm” study design allows 23 subjects at 15 sites to be evaluated. This is in contrast to the previous, 3-arm study of 84 patients.

Based on “other research efforts” mentioned above, Avita understands the “1:20 expansion ratio” is the best regime in this application as it used the “least amount of donor skin”.

Speaking on the release, Avita chief executive Dr Mike Perry said:

The design change allows this program to progress in a timely and cost-effective manner toward bringing a novel therapeutic option to an underserved population. Our ongoing multi-media outreach and clinical and advocacy group referral programs are generating significant interest in the trial.

Avita Medical share price snapshot

The Avita Medical share price has jumped following the announcement, landing in the green in midday trade. To illustrate, Avita shares are now exchanging hands at $4.76 apiece, a 0.85% jump from the open.

The Avita Medical share price has posted a loss of more than 3% this year to date, and 25% in the past 12 months.

These results have lagged the S&P/ASX 200 Index (ASX: XJO)’s return of around 25% over the past year.

The post Avita Medical (ASX:AVH) share price jumps on FDA approval appeared first on The Motley Fool Australia.

Should you invest $1,000 in Avita Medical right now?

Before you consider Avita Medical, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Avita Medical wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

5 ASX shares to hold for 5 years

3 small cap ASX shares to watch

2 ASX shares to hold onto for the next 5 years

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!